[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354425-105":59,"doc-detail-354425-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-circulating-gpnmb-based-multimodal-model-integrates-tumor-immune-crosstalk-to-predict-immunotherapy-response-in-esophageal-cancer","A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer","","Neoadjuvant immunotherapy benefits a subset of patients with esophageal squamous cell carcinoma (ESCC), but around 70% fail to respond. Plasma proteomics identified soluble GPNMB (sGPNMB) as the most elevated circulating protein in nonresponders. sGPNMB, produced by tumor cells, suppresses CD8+ T-cell receptor signaling via the SDC4-CD148 axis to drive functional exhaustion. In CAF-Epi niches, SOX2 transcriptionally activates GPNMB expression. Circulating GPNMB predicts PD-1 blockade response, and GPNMB inhibition synergizes with therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-circulating-gpnmb-based-multimodal-model-integrates-tumor-immune-crosstalk-to-predict-immunotherapy-response-in-esophageal-cancer/354425/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-circulating-gpnmb-based-multimodal-model-integrates-tumor-immune-crosstalk-to-predict-immunotherapy-response-in-esophageal-cancer/354425.png","ImageObject",300,407,{"name":92,"@type":93},"Ben ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are predictive biomarkers needed for ESCC immunotherapy?","Question",{"text":112,"@type":113},"Only about 30% of ESCC patients achieve durable benefit; many show primary resistance or relapse. Robust biomarkers are needed to guide patient selection and optimize treatment strategies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What circulating biomarker is highlighted in this study and how was it discovered?",{"text":117,"@type":113},"Soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB) was identified as the most elevated circulating protein in nonresponders using plasma proteomic profiling.",{"name":119,"@type":110,"acceptedAnswer":120},"How does sGPNMB contribute to immune resistance to PD-1 blockade?",{"text":121,"@type":113},"Tumor-derived sGPNMB suppresses CD8+ T-cell receptor signaling through the SDC4-CD148 axis, inducing functional exhaustion, and its secretion is required for immunosuppressive activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354425,1790182280,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ReseaRch aRticle  \nA Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in  \nEsophageal Cancer   \nLiang Zhu1,2, Xiaoyuan Wang3, Guoyu Cheng1,2, Yancheng Lai1,2, Lan Lan1,2, Zhenghao Dong1,2, Zhixuan You1,2, Xinjie Chen1,2, Ziyi He1,2, Xinyi Xiao1,2, Lingxuan Zhu1,2, Rucheng Liu1,2, Li Zhang4, Shaosen Zhang1,2, Dongxin Lin1,2,5,6, Chen Wu1,2,5,7, and Jiang Chang8  \nNeoadjuvant immunotherapy improves outcomes in esophageal squamous cell  \ncarcinoma (ESCC), yet ∼ 70% of patients fail to respond. Pretreatment biopsies and plasma provide critical opportunities for biomarker discovery. In this study, we performed plasma proteomic profiling and identified soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB) as the most elevated circulating protein in nonresponders. Mechanistically, tumor cell-derived sGPNMB suppressed CD8+ T-cell receptor signaling via the SDC4−CD148 axis to induce functional exhaustion, with secretion being required for its immunosuppressive activity. Cancer-associated fibroblast−epithelial (CAF-Epi) niches promoted SOX2 upregulation in tumor cells, transcriptionally activating GPNMB expression. In humanized patient-derived xenograft models, circulating GPNMB levels predicted response to PD-1 blockade, and GPNMB inhibition synergized with therapy. Across retrospective cohorts and a prospective clinical trial, a multimodal model combining plasma GPNMB levels, CAF-Epi niche detection, and clinical-pathologic features achieved robust predictive accuracy for immunotherapy response and survival. These findings establish a spatial-circulating biomarker framework for precision ESCC immunotherapy.  \nSIGNIfICANCE: Tumor-derived soluble GPNMB, transcriptionally activated by SOX2 within CAF-Epi niches, drives CD8+ T-cell exhaustion and resistance to PD-1 blockade in ESCC. Integrating circulating GPNMB levels with CAF-Epi niche features and clinical-pathologic factors, we develop and validate a clinically scalable multimodal model for predicting immunotherapy response.  \nintRoduction  \nImmune checkpoint inhibitors (ICIs) targeting PD-1/ PD-L1, CTLA-4, and emerging checkpoints such as LAG- 3, TIGIT, and TIM-3 restore antitumor T-cell activity by blocking inhibitory signaling (1) . ICIs have transformed the treatment landscape across multiple cancers, including melanoma, non–small cell lung cancer, breast cancer, and gastrointestinal malignancies (2–5) . In esophageal squamous cell carcinoma (ESCC), phase III trials, including KEYNOTE-590 (6), RATIONALE-306 (7), and ORIENT-15 (8), showed that combining PD-1 blockade with chemotherapy or chemoradiotherapy significantly improves pathologic complete response (pCR) rates and survival. These findings have established PD-1–based regimens as standard neoadjuvant strategies for locally advanced ESCC. However, only about 30% of patients with ESCC achieve durable benefit, whereas most exhibit primary resistance or relapse after initial response  \n1Department of Etiology and Carcinogenesis, National Cancer Center/ National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China. 2Key Laboratory of Cancer Genomic Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, China. 4Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 5Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China. 6Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China. 7CAMS Oxford Institute, Chinese Academy of Medical Sciences, Beijing, China. 8Department of Health Toxicology, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong ","cbCaidnHCFAFhcON","https://ap.wps.com/l/cbCaidnHCFAFhcON","pdf",25172478,22,"English","# Abstract\n## Immunotherapy challenge and biomarker need\n## Identification of circulating sGPNMB\n## Mechanistic pathway and niche regulation\n## Predictive multimodal model validation","[{\"question\":\"Why are predictive biomarkers needed for ESCC immunotherapy?\",\"answer\":\"Only about 30% of ESCC patients achieve durable benefit; many show primary resistance or relapse. Robust biomarkers are needed to guide patient selection and optimize treatment strategies.\"},{\"question\":\"What circulating biomarker is highlighted in this study and how was it discovered?\",\"answer\":\"Soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB) was identified as the most elevated circulating protein in nonresponders using plasma proteomic profiling.\"},{\"question\":\"How does sGPNMB contribute to immune resistance to PD-1 blockade?\",\"answer\":\"Tumor-derived sGPNMB suppresses CD8+ T-cell receptor signaling through the SDC4-CD148 axis, inducing functional exhaustion, and its secretion is required for immunosuppressive activity.\"}]","A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer | PDF",1790110571,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0ce097db89726264168dc7b6a894c85.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f52df14ba7ff26730377a4c59ffe545e.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b19348d870d1ec430c4db7b271f8763.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f04d59647bfa5b50301f2bc6af2368e8.webp",980,1311]